Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 5/20 | 0.36 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041572 | 0.89 | APEX1 (0.34) | SHMT1SHMT2LMNAKDM4EMAPT | |
| SCHEMBL13041557 | 0.75 | PTGDR2 (0.40) | KDM4EMAPTL3MBTL1 | |
| SCHEMBL13041569 | 0.70 | SHMT1 (0.33) | SHMT1SHMT2CDC7DBF4 | |
| SCHEMBL14609666 | 0.67 | GSK3B (0.37) | KDM4EMAPTPDE2AL3MBTL1PKM | |
| SCHEMBL2763388 | 0.67 | AGPAT2 (0.36) | AGPAT2SHMT1SHMT2LMNARORC | |
| SCHEMBL13710178 | 0.65 | HRH3 (0.41) | KDM4E | |
| SCHEMBL13761051 | 0.64 | HRH3 (0.40) | L3MBTL1 | |
| SCHEMBL13041564 | 0.64 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL2762868 | 0.62 | PTGDR2 (0.39) | LMNAKDM4EMAPTL3MBTL1 | |
| SCHEMBL10238182 | 0.61 | SLC6A3 (0.37) | LMNAKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956999-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| US-8956999-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| US-20100279868-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279868-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279868-A1 | NOVEL HERBICIDES | DDT, HPD, HSD17B1 | AGPAT2 572/4885SHMT1 376/4885SHMT2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.